I en undersøgelse med raske frivillige, ændrede daglig administration af etoricoxib 120 mg ikke hepatisk CYP3A4- aktivitet, vurderet ved erythromycin- pustetest.
In a study in healthy subjects, daily administration of etoricoxib 120 mg did not alter hepatic CYP3A4 activity as assessed by the erythromycin breath test.